Pharmacological inhibition of LSD1 represents a promising epigenetic approach for AML treatment through the release of the differentiation block and the induction of differentiation processes in leukemic blast cells [12, 19]. The gene discussed is KDM1A; the disease is acute myeloid leukemia.